Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

Professor M. Asim Beg and the COPCOV team at Aga Khan University in Pakistan © Asim Beg

"As of COB 29 July, COPCOV has now recruited 1637 participants -- making it the largest pre-exposure prophylaxis study in the world! There is still a way to go, as there remains so much potential in this study, but this is a fantastic milestone. Congratulations, everyone!" said COPCOV Co-PI Dr Will Schilling.

Funded by Wellcome and led by MORU, COPCOV is currently recruiting in Indonesia, Kenya, Zambia, Benin, Côte d’Ivoire and Mali. The global study hopes to open in the coming weeks new study sites in Benin, Ethiopia, Indonesia, Kenya, Nepal and Niger.

Recruitment into the COPCOV study at Aga Khan University slowed earlier in the year due to high COVID-19 vaccination coverage among healthcare worker staff. Following a change in recruitment strategy, the team pivoted to a community-based approach. Although this new approach presented many challenges, a tremendous effort from all those involved led, in less than six weeks, to 381 participants being recruited into COPCOV. This brought the total number of participants recruited at the site to 399 and marks a COPCOV milestone as Aga Khan becomes the first site to hit their recruitment target (400 could not be achieved due one study drug kit being damaged).

A huge congratulation to Professor M. Asim Beg (4th from left) and his team (shown celebrating their achievement 20 July) on this truly fantastic effort. 

-  James Callery, on behalf of the COPCOV team, with thanks to Asim Beg for photo.

Similar stories

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19